Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15106860 | 0.90 | MAPT (0.61) | ALDH1A1TDP1MAPTCYP1A2KDM4E | |
| SCHEMBL2129946 | 0.82 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPTCYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL29113808 | 0.81 | MEN1 (0.45) | ALDH1A1CYP1A2MEN1KMT2ATRPV1 | |
| SCHEMBL2169866 | 0.81 | MAPT (0.61) | ALDH1A1MAPTCYP1A2KDM4EMEN1 | |
| SCHEMBL29777188 | 0.78 | CYP1A2 (0.68) | ALDH1A1TDP1MAPTCYP1A2KDM4E | |
| SCHEMBL2133926 | 0.78 | CYP1A2 (0.68) | ALDH1A1TDP1MAPTCYP1A2KDM4E | |
| SCHEMBL16433384 | 0.75 | ALDH1A1 (0.51) | ALDH1A1TDP1MAPTCYP1A2KDM4E | |
| SCHEMBL162760 | 0.74 | MAPT (0.56) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL2171042 | 0.74 | MAPT (0.50) | ALDH1A1TDP1MAPTCYP1A2KDM4E | |
| SCHEMBL3659178 | 0.74 | ALDH1A1 (0.57) | ALDH1A1TDP1MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346836-B1 | PROCESSES FOR THE PREPARATION OF BENDAMUSTINE | CEPHALON INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-8420829-B2 | Processes for the preparation of bendamustine | CEPHALON, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110190509-A1 | Processes for the Preparation of Bendamustine | CEPHALON, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2346836-A1 | PROCESSES FOR THE PREPARATION OF BENDAMUSTINE | Cephalon, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010042568-A1 | PROCESSES FOR THE PREPARATION OF BENDAMUSTINE | CEPHALON, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190509-A1 | Processes for the Preparation of Bendamustine | THPO, FOLR1, FOLR2 | ALDH1A1 745/4885TDP1 2128/4885MAPT 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.